ANIPのチャート
ANIPの企業情報
| symbol | ANIP |
|---|---|
| 会社名 | ANI Pharmaceuticals Inc （ANIファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ANIファーマシューティカル（ANI Pharmaceuticals Inc.）は統合・専門的製薬会社である。同社はブランド医薬品とジェネリック医薬品の開発、製造、マーケティングに従事する。同社は抗癌剤（抗腫瘍剤）、ホルモンおよびステロイド、複合的製剤を提供する。同社はまた、他の製薬会社の請負製造を行う。製品には、ブランド医薬品とジェネリック医薬品を含む。ジェネリック医薬品はエリスロマイシンエチルコハク酸塩、メチルテストステロン（EEMT）を有するエステル化エストロゲン、エトドラクフェノフィブレート、フレカイニド、フルボキサミン、メタゾラミド、メトクロプラミドシロップニルタミド、ニモジピン、アヘンチンキ、オキシコドンカプセル、オキシコドン経口溶液、プロパフェノンおよびバンコマイシンなどを含む。ブランド製品にはコルテネーマ、インデラルLA、リトビッド、レグランおよびバンコシンが含まれる。同社の医薬品製造施設はミネソタ州ボーデットに位置する。 ANIファ―マシュ―ティカルズは米国の製薬会社。ブランドとジェネリックの医療用医薬品の開発、製造、販売に従事する。女性の性的健康、更年期障害、避妊と男性性腺機能低下症の治療用医薬品開発のほか、開発製品の対象は麻酔薬、抗がん薬、ホルモン・ステロイドおよび製剤を含む。本社はミネソタ州。 ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc. |
| 本社所在地 | 210 Main Street West Baudette MN 56623 USA |
| 代表者氏名 | Robert E. Brown ロバートE.ブラウン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 218-634-3500 |
| 設立年月日 | 35278 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 173人 |
| url | www.anipharmaceuticals.com |
| nasdaq_url | https://www.nasdaq.com/symbol/anip |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 62.04800 |
| 終値（lastsale） | 54.83 |
| 時価総額（marketcap） | 648570965.63 |
| 時価総額 | 時価総額（百万ドル） 656.49620 |
| 売上高 | 売上高（百万ドル） 189.20100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 806.10820 |
| 当期純利益 | 当期純利益（百万ドル） 13.49700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ANI Pharmaceuticals Inc revenues increased 15% to $93.8M. Net income applicable to common stockholders increased 31% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Stock-based Compensation in SGA decrease of 3% to $2.7M (expense). |
ANIPのテクニカル分析
ANIPのニュース
ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals 2023/05/31 01:12:20 Seeking Alpha
ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. See why I rate ANIP stock a Strong Buy here.
Looking Into ANI Pharmaceuticals''s Return On Capital Employed 2023/05/23 14:47:40 Benzinga
According to Benzinga Pro, during Q1, ANI Pharmaceuticals (NASDAQ: ANIP ) earned $1.44 million, a 133.91% increase from the preceding quarter. ANI Pharmaceuticals also posted a total of $106.79 million in sales, a 13.32% increase since Q4. In Q4, ANI Pharmaceuticals brought in $94.23 million in sales but lost $4.24 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative … Full story available on Benzinga.com
ANI Pharma Says FDA Approves Methsuximide Capsules, Alendronate Sodium Oral Solution 2023/05/15 11:28:14 RTT News
ANI Pharmaceuticals, Inc. (ANIP) announced Monday that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL.
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity 2023/05/15 10:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuximide Capsules has been granted 180-day Competitive Generic Therapy (CGT) Exclusivity, and Alendronate Sodium Oral Solution is eligible for CGT Exclusivity upon launch.
ANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Buy at StockNews.com 2023/05/14 07:38:31 EIN News Pharmaceuticals
… (Get Rating) ANI Pharmaceuticals , Inc is a bio- pharmaceutical company, which engages … marketing branded and generic prescription pharmaceuticals . Its areas of product development … '' ratings for ANI Pharmaceuticals and related companies with MarketBeat …
Earnings Preview For ANI Pharmaceuticals 2023/05/05 19:02:41 Benzinga
ANI Pharmaceuticals (NASDAQ: ANIP ) is set to give its latest quarterly earnings report on Monday, 2023-05-08. Here''s what investors need to know before the announcement. Analysts estimate that ANI Pharmaceuticals will report an earnings per share (EPS) of $0.35. ANI Pharmaceuticals bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
ANI Pharmaceuticals Q1 2023 Earnings Preview 2023/05/05 16:17:17 Seeking Alpha
ANI Pharmaceuticals (ANIP) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open.The consensus EPS Estimate is $0.35 (+391.7% Y/Y) and the consensus…
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET 2023/04/27 10:50:00 Business Wire
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial resul
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ 2023/04/26 20:15:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows: Date: Tuesday, May 2, 2023 Time: 12:00 p.m. ET Webcast: Click Here The webcast will be accessible on demand beginning on M
ANI Pharma Soars on FDA Approval for Furadantin Generic Version 2023/04/24 11:55:30 TipRanks
Shares of biopharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) are soaring higher today after the U.S. Food and Drug Administration (FDA) ap…
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET 2023/04/27 10:50:00 Business Wire
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial resul
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ 2023/04/26 20:15:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows: Date: Tuesday, May 2, 2023 Time: 12:00 p.m. ET Webcast: Click Here The webcast will be accessible on demand beginning on M
ANI Pharma Soars on FDA Approval for Furadantin Generic Version 2023/04/24 11:55:30 TipRanks
Shares of biopharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) are soaring higher today after the U.S. Food and Drug Administration (FDA) ap…
ANI Pharmaceuticals stock rises after FDA approval of generic antibiotic 2023/04/24 11:30:10 Seeking Alpha
ANI Pharmaceuticals (ANIP) said the U.S. FDA approved its generic antibacterial medicine Nitrofurantoin Oral Suspension. Read more here
ANI Pharma: FDA Approves ANDA For Nitrofurantoin Oral Suspension USP 2023/04/24 11:24:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) announced Monday that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application or ANDA for Nitrofuran…